Alligator Bioscience Ab Aktie - 0RK9

	Live streaming Echtzeit	Level 2
Euronext

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

23,00

Gebot

0,00

Fragen

0,00

Volumen

0,00

0,00 Tagesbereich 0,00

23,00 52-Wochen-Bereich 23,00

Marktkapitalisierung

15,133B

Handelsende

23,00

Handelsbeginn

Letzte Trade

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

2.201

Ausgegebene Aktien

657.954.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-60,88

Gewinn pro Aktie (EPS)

-0,38

Erlöse

59,27M

Nettogewinn

-248,59M

Sektor

Noncomml Resh Organizations

Branche

Noncomml Resh Organizations

Website

www.alligatorbioscience.se

Hauptsitz

Lund, Swe

Gegründet

Alligator Bioscience Ab is listed in the Noncomml Resh Organizations sector of the Londoner Börse with ticker 0RK9. The last closing price for Alligator Bioscience Ab was SEK23,00. Over the last year, Alligator Bioscience Ab shares have traded in a share price range of SEK 23,00 to SEK 23,00.

Alligator Bioscience Ab currently has 657.954.000 shares in issue. The market capitalisation of Alligator Bioscience Ab is SEK15,13 billion. Alligator Bioscience Ab has a price to earnings ratio (PE ratio) of -60.88.

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences PR Newswire LUND, Sweden, April 1, 2022 LUND...

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences PR Newswire LUND, Sweden, April 1, 2022 LUND...

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg PR Newswire LUND, Sweden, March 23, 2022 LUND, Sweden, March...

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg PR Newswire LUND, Sweden, March 23, 2022 LUND, Sweden, March...

Alligator Bioscience AB: Year End report January-December 2021

Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving...

Alligator Bioscience AB: Year End report January-December 2021

Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving...

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer PR Newswire LUND, Sweden, Feb. 1, 2022 LUND, Sweden, Feb. 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq...

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer PR Newswire LUND, Sweden, Feb. 1, 2022 LUND, Sweden, Feb. 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq...

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR Newswire LUND, Sweden, Jan. 19, 2022 LUND, Sweden...

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR Newswire LUND, Sweden, Jan. 19, 2022 LUND, Sweden...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	23	23	23	2768	23	DE
4	23	23	23	5401	23	DE
12	23	23	23	2201	23	DE
26	23	23	23	1521	23	DE
52	23	23	23	2244	23	DE
156	23	23	23	1418	23	DE
260	23	23	23	1672	23	DE

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
0A2IH World Group Ltd	US$ 0,00 (0,00%)	0
0A2DCrh Plc	US$ 0,00 (0,00%)	0
0A2BBanco Bilbao Vizcaya Argentaria Sa	US$ 0,00 (0,00%)	0
0A22Anheuser Busch Inbev Nv	US$ 0,00 (0,00%)	0
0A1UUber Technologies Inc	US$ 72,15 (0,00%)	2,94k
0A2IH World Group Ltd	US$ 0,00 (0,00%)	0
0A2DCrh Plc	US$ 0,00 (0,00%)	0
0A2BBanco Bilbao Vizcaya Argentaria Sa	US$ 0,00 (0,00%)	0
0A22Anheuser Busch Inbev Nv	US$ 0,00 (0,00%)	0
0A1UUber Technologies Inc	US$ 72,15 (0,00%)	2,94k
ARBArgo Blockchain Plc	8,10p (0,00%)	9,7M
0R0XTesla Inc	US$ 339,20 (0,00%)	21,28k
0A6LGamestop Corp	US$ 29,9025 (0,00%)	3,77k
0HCIAlibaba Group Holding Ltd	US$ 86,90 (0,00%)	3,07k
0A1UUber Technologies Inc	US$ 72,15 (0,00%)	2,94k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Alligator Bioscience Ab (0RK9)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Alligator Bioscience Ab

0RK9 Neueste Nachrichten

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg

Alligator Bioscience AB: Year End report January-December 2021

Alligator Bioscience AB: Year End report January-December 2021

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

BLACK FRIDAY

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Alligator Bioscience Ab (0RK9) Börsenkurse

Alligator Bioscience Ab (0RK9)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Alligator Bioscience Ab

0RK9 Neueste Nachrichten

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

BLACK FRIDAY

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%